-Bisphosphonates including (alendronate, risedronate, and zoledronic acid) are preferred agents for the treatment of postmenopausal osteoporosis.
-Bisphosphonates bind to hydroxyapatite crystals in the bone and decrease osteoclastic bone resorption, resulting in an increase in bone mass and adecreased risk of fractures.
-The effects of bisphosphonates on bone are long-lasting Oral bisphosphonates for osteoporosis (alendronate, risedronate,
ibandronate) are associated with esophagitis and esophageal
ulcers,To minimize esophageal irritation, patients should remain
upright after taking oral bisphosphonates.
-Food and other medications significantly interfere with
absorption of oral bisphosphonates.
-Intravenous bisphosphonates for osteoporosis include zoledronic acid and ibandronate.
-Zoledronic acid is administered once per year as an intravenous infusion.
-Rare, but serious, adverse effects of the bisphosphonates
include ONJ(osteonecrosis of the jaw) and atypical femur fractures.
-These effects are more likely with a longer duration of therapy Therefore, adrug holiday should be considered for patients after 5 years of oral bisphosphonates or 3 years of zoledronic acid.
-Denosumab is a RANKL inhibitor that is an alternative first-line agent
for postmenopausal osteoporosis, particularly in patients at higher risk
of fractures. It is administered every 6 months as a subcutaneous injection.
-The parathyroid agents teriparatide and abaloparatide act as agonists
at the parathyroid hormone receptor to stimulate osteoblastic activity
and increase bone formation and strength, Due to the risk of osteosarcoma, use of these agents is limited to 2 years.
-Romosozumab is a sclerostin inhibitor, thereby promoting osteoblast activity and bone formation, It is administered as aonce-monthly subcutaneous injection for 12 months.
-In the treatment of osteoporosis, teriparatide, abaloparatide, and
romosozumab should be reserved for individuals at very high risk of
fractures.
-Summary chapter osteoporosis.
-Bisphosphonates bind to hydroxyapatite crystals in the bone and decrease osteoclastic bone resorption, resulting in an increase in bone mass and adecreased risk of fractures.
-The effects of bisphosphonates on bone are long-lasting Oral bisphosphonates for osteoporosis (alendronate, risedronate,
ibandronate) are associated with esophagitis and esophageal
ulcers,To minimize esophageal irritation, patients should remain
upright after taking oral bisphosphonates.
-Food and other medications significantly interfere with
absorption of oral bisphosphonates.
-Intravenous bisphosphonates for osteoporosis include zoledronic acid and ibandronate.
-Zoledronic acid is administered once per year as an intravenous infusion.
-Rare, but serious, adverse effects of the bisphosphonates
include ONJ(osteonecrosis of the jaw) and atypical femur fractures.
-These effects are more likely with a longer duration of therapy Therefore, adrug holiday should be considered for patients after 5 years of oral bisphosphonates or 3 years of zoledronic acid.
-Denosumab is a RANKL inhibitor that is an alternative first-line agent
for postmenopausal osteoporosis, particularly in patients at higher risk
of fractures. It is administered every 6 months as a subcutaneous injection.
-The parathyroid agents teriparatide and abaloparatide act as agonists
at the parathyroid hormone receptor to stimulate osteoblastic activity
and increase bone formation and strength, Due to the risk of osteosarcoma, use of these agents is limited to 2 years.
-Romosozumab is a sclerostin inhibitor, thereby promoting osteoblast activity and bone formation, It is administered as aonce-monthly subcutaneous injection for 12 months.
-In the treatment of osteoporosis, teriparatide, abaloparatide, and
romosozumab should be reserved for individuals at very high risk of
fractures.
-Summary chapter osteoporosis.
❤29❤🔥4👏2
9,000 subscribers
Thanks for trust
In the end , Quality matter not Quantity 🤍❤🔥71😁3💊1
Forwarded from Pharmacy final stage (مصطفى النعيمي)
Lec 1 + 2 + 3 summary.pdf
1.3 MB
.
ملخص لكجر 1،2،3
ملخص لكجر 1،2،3
❤🔥1❤1
Forwarded from Pharmacy final stage (مصطفى النعيمي)
Lec 4 summary .pdf
330.6 KB
.
ملخص لكجر 4
ملخص لكجر 4
❤🔥1❤1
Forwarded from Pharmacy final stage (مصطفى النعيمي)
Lec 5 summary .pdf
725.8 KB
.
ملخص لكجر 5
ملخص لكجر 5
سكري جدول.pdf
220.1 KB
.
جدول لادوية السكري كامل
جدول لادوية السكري كامل
❤2❤🔥1
Forwarded from Pharmacy final stage (مصطفى النعيمي)
Lec 6 summary.pdf
1 MB
.
ملخص لكجر 6
ملخص لكجر 6
❤2❤🔥1
Forwarded from Pharmacy final stage (مصطفى النعيمي)
Lec 7 summary .pdf
507.8 KB
.
ملخص لكجر 7
ملخص لكجر 7
❤3❤🔥1
Forwarded from Pharmacy final stage (مصطفى النعيمي)
Lec 8 summary .pdf
685.4 KB
.
ملخص لكجر 8
ملخص لكجر 8
Lec 9 summary .pdf
521.6 KB
.
ملخص لكجر 9
ملخص لكجر 9
❤8❤🔥1